Boards & Committees - Corporate Development




COMMITTEE COMPOSITION

  • The Corporate Development Committee shall consist of a Chair (the Treasurer of the Society) and four members appointed by the Board for 2-year staggered terms, renewable twice.
  • One member shall represent heart, one shall represent lung, one shall represent MCS, and one shall represent PH.
  • The President, President-Elect, and Executive Director shall also serve as members of the Corporate Development Committee.


COMMITTEE RESPONSIBILITIES

  • Work with the Board and Scientific Councils to identify strategic opportunities related to industry partnerships.
  • Work with the Executive Director to develop the Society’s annual corporate partner opportunities.
  • Meet with company representatives to discuss ISHLT’s programs and activities and potential areas for collaboration with companies.
  • Serve as the responsible entity for negotiating corporate support partnerships.
  • Seek assistance, as needed, from the Scientific Council Operating Boards to establish relationships with companies and to negotiate support agreements.
CORPORATE DEVELOPMENT COMMITTEE


COMMITTEE CHAIR:
ISHLT TREASURER
Joseph Rogers, MD
Duke University Medical Center
Durham, NC, USA





ISHLT PRESIDENT
Andrew J. Fisher, FRCP, PhD
Freeman Hospital
Newcastle Upon Tyne, UK





ISHLT PRESIDENT-ELECT
Jeffrey J. Teuteberg, MD (2019)
Stanford University School of Medicine
Stanford, CA, USA





EXECUTIVE DIRECTOR
Amanda Rowe
ISHLT
Addison, Texas, USA






CORPORATE DEVELOPMENT COMMITTEE


COMMITTEE CHAIR:
ISHLT TREASURER
Joseph Rogers, MD
Duke University Medical Center
Durham, NC, USA
ISHLT PRESIDENT
Andrew J. Fisher, FRCP, PhD
Freeman Hospital
Newcastle Upon Tyne, UK
ISHLT PRESIDENT-ELECT
Jeffrey J. Teuteberg, MD (2019)
Stanford University School of Medicine
Stanford, CA, USA
EXECUTIVE DIRECTOR
Amanda Rowe
ISHLT
Addison, Texas, USA
Text SizeIncrease Font SizeDecrease Font Size